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Abstract
Purpose—Aberrant vascular endothelial growth factor (VEGF) and platelet-derived growth
factor (PDGF) signaling have been shown to play a role in non–small-cell lung cancer (NSCLC)
pathogenesis and are associated with decreased survival. We evaluated the clinical activity and
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tolerability of sunitinib malate (SU11248), an oral, multitargeted tyrosine kinase inhibitor that
blocks the activity of receptors for VEGF and PDGF, as well as related tyrosine kinases in patients
with previously treated, advanced NSCLC.
Patients and Methods—Patients with stage IIIB or IV NSCLC for whom platinum-based
chemotherapy had failed received 50 mg/d of sunitinib for 4 weeks followed by 2 weeks of no
treatment in 6-week treatment cycles. The primary end point was objective response rate (ORR);
secondary end points included progression-free survival, overall survival, and safety.
Results—Of the 63 patients treated with sunitinib, seven patients had confirmed partial
responses, yielding an ORR of 11.1% (95% CI, 4.6% to 21.6%). An additional 18 patients
(28.6%) experienced stable disease of at least 8 weeks in duration. Median progression-free
survival was 12.0 weeks (95% CI, 10.0 to 16.1 weeks), and median overall survival was 23.4
weeks (95% CI, 17.0 to 28.3 weeks). Therapy was generally well tolerated.
Conclusion—Sunitinib has promising single-agent activity in patients with recurrent NSCLC,
with an ORR similar to that of currently approved agents and an acceptable safety profile. Further
evaluation in combination with other targeted agents and chemotherapy in patients with NSCLC is
warranted.
INTRODUCTION
Lung cancer remains the leading cause of cancer-related mortality worldwide, accounting
for 1.18 million deaths per year.1 New agents using novel treatment approaches are needed
to improve survival outcomes. Recent nonclinical and clinical studies have identified critical
biologic pathways in non–small-cell lung cancer (NSCLC), including vascular endothelial
growth factor (VEGF) and platelet-derived growth factor (PDGF), which are growth factors
that play an important role in tumor growth. Elevated expression of VEGF is a strong
prognostic indicator in NSCLC and is associated with early postoperative relapse and
decreased survival,2 and increased expression of PDGF has also been associated with poor
prognosis in NSCLC.3,4 Furthermore, these pathways may cooperate in neoangiogenesis. In
nonclinical studies using human lung squamous cell carcinoma and adenocarcinoma cell
lines, as well as surgically resected fresh human NSCLC samples, PDGF-AA (which binds
to the PDGF receptor [PDGFR]-α) was shown to be an essential regulator of VEGF
expression.5,6 Thus PDGF as well as VEGF pathways are rational targets for antiangiogenic
therapy in NSCLC and rational targets for anticancer therapy. Therefore, multitargeted
inhibition of angiogenic pathways may be a more effective therapy for NSCLC than single-
pathway inhibition.
Clinical studies with bevacizumab, a monoclonal antibody directed against the VEGF-A
ligand, have shown that targeting angiogenesis increases the efficacy of conventional
chemotherapeutic regimens in NSCLC.7–9 In a phase II/III study evaluating carboplatin and
paclitaxel in patients with advanced disease who had not received prior treatment,8 the
addition of bevacizumab to carboplatin and paclitaxel treatment significantly improved
response rate (35% v 15%; P < .001), median progression-free survival (6.2 v 4.5 months;
P<.001), and median overall survival (12.3 v 10.3 months; P = .003).
Sunitinib malate is an oral, selective multitargeted tyrosine kinase inhibitor with
antiangiogenic and antitumor activities. It inhibits VEGF receptor (VEGFR)-1, -2, and -3
and PDGFR-α and -β activity, as well as the activity of several related tyrosine kinases10–13
(Pfizer Inc; data on file). In preclinical studies, sunitinib effectively inhibited the growth of
established human NSCLC xenografts,11 and antitumor activity has also been observed in
patients with NSCLC in a phase I study.14 Phase III studies with sunitinib in other types of
cancers have shown clinical efficacy with acceptable tolerability at a dose of 50 mg/d
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administered for 4 weeks, followed by 2 weeks of no treatment, in repeated 6-week
cycles.15–17 This treatment regimen was used in the current phase II, open-label, multicenter
study to evaluate the clinical activity and tolerability of sunitinib in patients with advanced
NSCLC previously treated with platinum-based chemotherapy.
PATIENTS AND METHODS
Patients
Male and female patients 18 years of age or older had histologically proven stage IIIB or IV
NSCLC which had progressed during or after treatment with at least one platinum-based
combination chemotherapy regimen. Up to two prior systemic chemotherapy regimens were
permitted regardless of the number of prior treatments with an epidermal growth factor
receptor inhibitor. All patients had unidimensionally measurable disease; evidence of
disease progression within 6 months of their most recent prior systemic anticancer
treatment; an Eastern Cooperative Oncology Group performance status of 0 or 1; adequate
hepatic, renal, and hematologic function; and had provided informed consent. Patients were
excluded if they had had a grade 3 hemorrhage, based on the National Cancer Institute
(NCI) Common Terminology Criteria for Adverse Events (CTCAE), or gross hemoptysis (>
5 mL of blood per episode and > 10 mL of blood/d) less than 4 weeks before beginning
treatment. Previous treatment with antiangiogenic agents was not permitted. Additional
reasons for exclusion included uncontrolled hypertension; diagnosis of any second
malignancy within the last 5 years (except for adequately treated basal cell or squamous cell
skin cancer or in situ carcinoma of the cervix uteri); a history of or known brain metastases,
spinal cord compression or carcinomatous meningitis or evidence of brain or leptomeningeal
disease based on computed tomography or magnetic resonance imaging scans; clinically
significant cardiovascular disease (severe/unstable angina, myocardial infarction, coronary
artery bypass graft, symptomatic congestive heart failure), pulmonary embolism or
cerebrovascular accident within 12 months before study drug administration; a history of a
decline in left ventricular ejection fraction that was below the lower limit of normal; or
ongoing cardiac dysrhythmias (NCI CTCAE grade ≥ 2), atrial fibrillation, or prolongation of
the QTc interval.
Study Design and Treatment
In this phase II, open-label, multicenter study, patients received sunitinib in 6-week cycles,
comprising once-daily treatment for 4 consecutive weeks, followed by 2 weeks of no
treatment (schedule 4/2). Sunitinib was self-administered orally in the morning without
regard to meals at a starting dose of 50 mg/d. When required, based on individual patient
tolerability, subsequent doses were adjusted to 37.5 mg/d and then to 25 mg/d by study
investigators, and therapy could be interrupted or delayed for up to 4 weeks (in addition to
the scheduled 2-week off-treatment period). Treatment was otherwise administered for up to
54 weeks until disease progression or withdrawal of consent occurred.
The study was approved by the institutional review board of each participating center and
was carried out in accordance with the International Conference on Harmonization Good
Clinical Practice guidelines protocol, as well as applicable local laws and regulatory
requirements.
The protocol was amended to examine the efficacy and safety of continuous daily sunitinib
treatment at a starting dose of 37.5 mg in an additional cohort of patients; these results will
be reported separately.
Socinski et al. Page 3














The primary end point of this study was the overall confirmed objective response rate
(ORR), defined as the percentage of patients with confirmed complete responses (CRs) or
partial responses (PRs) based on radiologic tumor assessments (computed tomography,
magnetic resonance imaging, and bone scans as appropriate) and the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria.18 Imaging scans included the chest, abdomen,
and pelvis and were collected at the end of dosing in cycles 1 to 4, 6, and 8, and at study
termination. Bone scans were collected at the same interval if bone metastases were present
at screening, and brain and/or bone scans were performed if metastases were suspected in
these regions during the study. Scans were also performed 4 weeks after observation of an
initial PR for response confirmation according to RECIST criteria.
Other evaluations included medical history, physical examination (including height, weight,
and vital sign measurements), laboratory tests (urinalysis, hematology, coagulation, and
blood chemistry), and assessment of Eastern Cooperative Oncology Group performance
status, cardiac function (12-lead ECGs), and adverse events (AEs; graded using the NCI
CTCAE, version 3.0).
Progression-free survival (PFS), duration of response (DR), overall survival (OS), and the 1-
year survival rate were evaluated as secondary end points of the study.
Statistical Methods
On the basis of a two-stage Simon Minimax design19 with an α level of 10% and 90%
power, 60 patients (39 patients in stage 1 of the study and an additional 21 patients in stage
2) were required to test the null hypothesis that the true ORR was ≤ 5% versus the
alternative hypothesis that the true ORR was ≥ 15%. At least two confirmed objective
responses were needed in stage 1 to allow expansion of the trial to stage 2. At the end of the
study, at least six confirmed objective responses were needed to reject the null hypothesis.
Efficacy (and safety) analyses included all patients who received at least one dose of
sunitinib. The number and proportion of patients who achieved an objective response (CR or
PR) was summarized along with the corresponding exact two-sided 95% CI, calculated
using a method based on the F distribution. PFS, DR, and OS were summarized using the
Kaplan-Meier method,20 with the median event time and a two-sided 95% CI for the median
provided for each end point.21 The 1-year survival rate was estimated using the Kaplan-
Meier method, and a two-sided 95% CI interval for the log(−log[1-year survival rate]) was
calculated using a normal approximation and then back transformed to give a CI for the 1-
year survival rate.
RESULTS
A total of 64 patients from 10 centers in the United States and Europe were enrolled onto the
cohort of patients assigned to schedule 4/2 dosing in the study. Sixty-three patients received
at least one dose of sunitinib. Baseline characteristics are listed in Table 1 and show a
median age of 60 years, male predominance, and a good performance status and history of
smoking in a majority of patients. Sixty-four percent of patients (n = 40) had been diagnosed
with adenocarcinoma of the lung, and 22% had been diagnosed with squamous cell
carcinoma of the lung. Stage IV disease was present in 90% of patients (n = 57). All patients
received chemotherapy before study enrollment, including a platinum agent in 94% (n = 59);
60% (n = 38) of the patients had received two or more systemic treatments before study
entry. The starting dose of sunitinib was 50 mg/d on schedule 4/2 for all 63 patients who
received at least one dose of sunitinib. The median duration of sunitinib treatment was 11
weeks (range, 1 to 54 weeks; Table 2). No patients remain on treatment; 65% (n = 41)
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discontinued therapy because of disease progression; 29% (n = 18) discontinued because of
an AE, and 3% (n = 2) of patients completed all nine cycles of treatment (Table 2).
Safety/Tolerability
The most commonly reported AEs include fatigue/asthenia, pain/myalgia, nausea/vomiting,
and stomatitis/mucosal inflammation. Most AEs were mild to moderate in severity (grades 1
to 2; Table 3) and did not interfere with scheduled treatment. Grade 3 or 4 AEs included
fatigue/asthenia (29%), pain/myalgia (17%), dyspnea (11%), and nausea/vomiting (10%;
Table 3). Grade 3 hypertension, which was reported in three patients (5%), was managed
according to standard clinical practice, combined with sunitinib dose interruption and/or
reduction if necessary. Lymphopenia was the most common grade 3 or 4 hematologic,
treatment-emergent AE (Table 3) and occurred at grade 3 in 12 patients (20%) and at grade
4 in three patients (5%). Grade 3 and 4 thrombocytopenia occurred in two patients (3%) and
one patient (2%), respectively; similarly, grade 3 and 4 neutropenia occurred in two patients
(3%) and one patient (2%), respectively. However, no cases of febrile neutropenia were
observed.
Transient dose interruption occurred in 15 patients (24%), and 14 patients (22%) underwent
a dose reduction (to 37.5 mg in 11 patients and to 25 mg in three patients). Seventeen
patients permanently discontinued sunitinib because of one or more AEs (excluding disease
progression), for a total of 31 AEs leading to discontinuation. The most commonly reported
AEs leading to permanent discontinuation of sunitinib included fatigue (four patients),
asthenia (three patients), diarrhea (two patients), and vomiting (two patients).
A total of 19 patients died while enrolled onto the study. Disease progression was the cause
of death for 13 patients, and six patients died as a result of other causes. Three hemorrhage-
related deaths occurred on study, two of which were treatment-related; grade 5 pulmonary
hemorrhage which was assessed as treatment-related occurred in a 62-year-old female
patient with squamous cell lung cancer 7 days after the patient’s last dose of sunitinib and 27
days after her first dose. In another squamous cell lung cancer case, a 77-year-old male
patient developed grade 4 pulmonary hemorrhage followed by death owing to disease
progression. A cerebral hemorrhage occurred in a 73-year-old male patient with
adenocarcinoma and was reported as treatment-related. This event occurred 6 days after the
patient’s last dose and 20 days after his first dose of medication and was associated with the
development of brain metastasis in the frontal lobe. Grade 5 hemorrhage was also reported
in a 68-year-old female patient who developed an extensive hematoma of the face and arm
after a failed attempt at intravenous access into the subclavian vein at a time when the
patient was anticoagulated for pulmonary embolism; this event occurred 1 day after the
patient’s last dose of sunitinib and 77 days after her first dose. The remaining on-study
deaths were due to disseminated intravascular coagulation, pneumothorax, and stroke. The
first two cases were judged by the investigator to be related to study drug.
In addition to the deaths occurring on study, 34 patients died during study follow-up, with
33 deaths attributed to progressive disease and one death resulting from traumatic injury.
Efficacy
Seven patients achieved a confirmed objective response (all PRs), giving an ORR of 11.1%
(95% CI, 4.6% to 21.6%). An additional 18 patients (28.6%) had a best response of stable
disease for 8 weeks or longer. The median DR was 21.2 weeks (range, 4.4+ to 36.3+ weeks),
and the median duration of stable disease was 22.1 weeks (range, 10.1 to 46.3 weeks).
Baseline characteristics of the seven patients with a confirmed PR are shown in Table 4 and
are generally representative of the larger patient population. Most of the patients with a PR
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had a history of smoking, stage IV adenocarcinoma of the lung, and had previously received
treatment with a platinum-based doublet. Interestingly, five of the seven responses were
observed in women.
Some degree of target lesion shrinkage was observed in the majority of the patients (44 of
63 patients; 70%). Tumor assessments performed on-study revealed 15 patients (24%) with
a maximum decrease in target lesion measurements of at least 30% when compared with
screening. In addition to the seven patients with a confirmed PR, one patient was
unassessable because of the absence of restaging bone scan, but this patient otherwise met
RECIST criteria for a confirmed PR. The other seven patients did not meet RECIST criteria
for a confirmed PR as a result of disease progression at the subsequent imaging assessment
(n = 6) or death before reimaging (n = 1). Disease progression was documented with a new
lesion (n = 3, one patient each with bone, adrenal, and brain metastasis), target lesion
measurement increase (n = 1), target lesion measurement increase and progression of a
nontarget lesion (n = 1), and target lesion measurement increase and development of a new
lesion (n = 1). Best response for target lesion(s) by patient is shown in the waterfall plot in
Fig 1.
Median PFS was 12.0 weeks (95% CI, 10.0 to 16.1 weeks; Fig 2A), and median OS was
23.4 weeks (95% CI, 17.0 to 28.3 weeks; Fig 2B). The 1-year survival rate was 20.2% (95%
CI, 10.0% to 30.4%).
DISCUSSION
In NSCLC, as inmost solid tumors, it is believed that there is multilevel cross-stimulation
among targets along several pathways of signal transduction that lead to malignancy. As
most first-generation targeted agents act by blocking only one of these pathways, other
pathways are allowed to act as salvage or escape mechanisms for cancer cells. Therefore, a
logical approach would involve a single agent with multiple targets, which, in combination
with chemotherapy, may provide a more complete therapeutic benefit. Such agents include a
number of small-molecule tyrosine kinase inhibitors that target several receptor tyrosine
kinases associated with NSCLC and activated vascular endothelial cells.
The potential advantages of multitargeted tyrosine kinase inhibitors over single-targeted
agents may include convenience of multiactivity in single agent, higher likelihood of single-
agent activity, direct targeting of both tumor and blood vessels, and potentially lower costs.
These possible benefits must be weighed against potential disadvantages; for instance, the
inhibition of each target may not be equally effective at the relevant dose used in patients,
and the potential exists for different toxicity profiles for multitargeted agents compared with
single-targeted agents.
Preclinical data have shown benefits for combining VEGFR and PDGFR inhibition in terms
of tumor regression in the H266 human lung carcinoma model.22 The antitumor activity of
single-agent sunitinib in mouse models is similar to that observed with the combination of a
PDGFR/kit inhibitor with a selective VEGFR inhibitor and superior to either agent
administered alone.22 These data support the importance of dual inhibition of VEGFR and
PDGFR for antitumor activity. The importance of these signaling pathways has been further
evaluated in patients with NSCLC, where aberrant VEGF and PDGF signal transduction is
associated with decreased survival and tumor angiogenesis.2,3
Clinical trials with the anti-VEGF monoclonal antibody bevacizumab have confirmed the
importance of VEGF pathways in advanced NSCLC, showing that the addition of an anti-
VEGF agent to chemotherapy improves survival when compared with chemotherapy alone.8
However, the importance of PDGF pathways is increasingly recognized.3–5 In the present
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study, sunitinib, an inhibitor of both VEGFR and PDGFR, has demonstrated single-agent
activity in patients with previously treated, advanced NSCLC with an ORR of 11.1%.
Similar response rates in this disease setting have not been previously reported for an
antiangiogenic agent, suggesting that the broader and/or more complete inhibition of
angiogenic pathways of sunitinib can effect greater antitumor activity.
As shown in Fig 1, the majority of patients demonstrated some reduction in the target lesion
measurements while enrolled onto the study. However, the activity of sunitinib and other
antiangiogenic agents may still be underestimated by RECIST criteria. Some patients who
showed small changes in tumor measurements demonstrated tumor cavitation, suggesting
clinical efficacy might not always result in decreases in target lesion measurements.
Docetaxel, pemetrexed, and erlotinib are approved for patients with recurrent NSCLC.23–25
Single-agent treatment with docetaxel results in an ORR of 6.7% to 10.8% and a median OS
of 5.5 to 7.5 months.23,26 Pemetrexed and erlotinib have shown similar response rates.24,25
The clinical activity of sunitinib observed in the current study seems similar to the currently
approved agents despite the evaluation of sunitinib in a more heavily pretreated patient
population, with the majority (60%) of the sunitinib-treated patients having received two or
more prior systemic treatment regimens.
The AEs observed in this study were either expected for this patient population or similar to
those reported in other trials of sunitinib.15–17 Sunitinib was generally well tolerated, with
the majority of AEs being grade 1 or 2 in nature. Preliminary analysis of the additional
patients (n = 47) treated on the continuous schedule of sunitinib at 37.5 mg/d suggest a
lower rate of severe fatigue.27,28 In addition, evidence suggests that hemorrhage seems to
occur with antiangiogenic agents in NSCLC,29 as described in this study. Hematologic
toxicity was minimal, but careful phase I/II trials of sunitinib combined with standard
cytotoxic agents must be undertaken to be sure sunitinib does not worsen hematologic
toxicity, as has previously been observed with bevacizumab.8
In conclusion, this study shows that sunitinib has promising single-agent activity and a
manageable tolerability profile in patients with recurrent NSCLC. The clinical activity of
sunitinib in this heavily pretreated population of patients was similar to that of currently
approved agents. This study has been amended to evaluate an alternative sunitinib treatment
schedule comprising continuous once-daily dosing at 37.5 mg/d.27 Given the preliminary
evidence of sunitinib activity in NSCLC, additional studies are currently underway,
including trials of sunitinib in combination with chemotherapy or molecularly targeted
agents and trials evaluating sunitinib as maintenance therapy in those patients who derive
clinical benefit from first-line platinum-based chemotherapy.
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Best response for target lesions by patient, based on maximal percentage of tumor reduction.
Patients experiencing a partial response according Response Evaluation Criteria in Solid
Tumors (RECIST) are shown in yellow bars, while those with stable disease or progressive
disease are shown in blue bars. (Some patients withdrew from the study before their first
postscreening scan.)
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Kaplan-Meier plots of (A) progression-free survival (PFS) and (B) overall survival (OS).
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Table 1
Patient Characteristics at Baseline





    Median 60
    Range 33–86
Sex
    Male 41 65
    Female 22 35
ECOG performance status
    0 28 4
    1 35 56
Smoking status
    Ever 50 79
    Never 10 16
    Not known 3 5
NSCLC histology
    Adenocarcinoma 40 64
    Squamous cell carcinoma 14 22
    Bronchioloalveolar 2 3
    Large-cell carcinoma 2 3
    NSCLC NOS 5 8
Disease stage
    IIIB 6 10
    IV 57 90
Metastatic sites
    Lymph nodes 39 62
    Bone 24 38
    Pleural effusion 15 24
    Liver 13 21
    Soft tissue 11 18
    Adrenal gland 7 11
    Skin 5 8
    Peritoneal 1 2
    Other 9 14
No. of prior systemic regimens
    1 25 40
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    2 30 48
    ≥ 3 8 13
No. of prior chemotherapy regimens
    1 37 59
    2 23 36
    ≥ 3 3 5
Prior treatments 63 100
    Platinum agent 59 94
      Carboplatin 42 67
      Cisplatin 19 30
    Gemcitabine 34 54
    Paclitaxel 24 38
    Docetaxel 19 30
    Pemetrexed 6 10
    EGFR inhibitor* 21 33
      Erlotinib 12 19
      Gefitinib 10 16
      Cetuximab 2 3
    Other 9 14
Abbreviations: ECOG, Eastern Cooperative Oncology Group; NSCLC, non–small-cell lung cancer; NOS, not otherwise specified; EGFR,
epidermal growth factor receptor.
*
Cetuximab, erlotinib, or gefitinib.
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Table 2
Treatment Duration and Patient Disposition





    Median 11
    Range 1–54
Treatment interruption 15 24
    Adverse event 14 22
    Other 2 3
Dose reduction 14 22
    Reductions to 37.5 mg 11 17
    Reductions to 25 mg 3 5
Primary reason for treatment discontinuation
    Disease progression 41 65
    Adverse events 18* 29
    Consent withdrawn 2 3
    Patient completed study per protocol 2 3
*
Includes one patient for whom the adverse event was grade 5 disease progression.
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